Myriad Genetics Inc. (MYGN)

29.17
0.76 2.68
NASDAQ : Health Technology
Prev Close 28.41
Open 28.53
Day Low/High 28.26 / 29.27
52 Wk Low/High 18.01 / 41.57
Volume 420.19K
Avg Volume 694.80K
Exchange NASDAQ
Shares Outstanding 69.85M
Market Cap 2.00B
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Myriad Genetics Is Poised for a Rebound on the Charts

Myriad Genetics Is Poised for a Rebound on the Charts

Is this stock a buy? Hold? Or sell? Let's look at some updated charts.

Dropbox, Qualcomm, Skechers: 'Mad Money' Lightning Round

Dropbox, Qualcomm, Skechers: 'Mad Money' Lightning Round

Jim Cramer focuses on Dropbox, Qualcomm, Skechers USA, Spotify, Nucor, Kratos Defense & Security, American Water Works.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Myriad Receives Pre-Market Approval For Its BRACAnalysis® Diagnostic System In Japan

Myriad Receives Pre-Market Approval For Its BRACAnalysis® Diagnostic System In Japan

Indicated as a Companion Diagnostic for Lynparza® (olaparib) for Use in Patients With Metastatic Inoperable or Recurrent Breast Cancer

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Myriad Genetics, Inc. Investors (MYGN)

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Myriad Genetics, Inc. Investors (MYGN)

Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces Investigation On Behalf Of Myriad Genetics, Inc. (MYGN) Investors

INVESTOR ALERT: Kirby McInerney LLP Announces Investigation On Behalf Of Myriad Genetics, Inc. (MYGN) Investors

The law firm of Kirby McInerney LLP announced today an investigation on behalf of Myriad Genetics, Inc.

Myriad Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer

Myriad Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer

Position Statement Also Supports Access to Hereditary Cancer Testing for Prostate Cancer

Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer As Part Of National Colorectal Cancer Awareness Month

Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer As Part Of National Colorectal Cancer Awareness Month

Myriad Teams Up with Fight Colorectal Cancer to Support the #StrongArmSelfie Social Media Campaign throughout March

NCCN Guidelines Broadly Endorse Biomarker Testing In Prostate Cancer

NCCN Guidelines Broadly Endorse Biomarker Testing In Prostate Cancer

Prolaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 Prostate Cancer Patients per Year

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score In Early-Stage Breast Cancer

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score In Early-Stage Breast Cancer

Large National Payer Expands Coverage Policy to Include EndoPredict for Guiding Extended Hormone Therapy for Patients with ER+ Breast Cancer

TheStreet Quant Rating: C+ (Hold)